Evidence map›Paper›PMID 41979785›Full record

ReviewScience China. Life sciences2026

Chemical adaptation: bridging synthetic chemistry with drug development.

Ke Ding, Yupeng Li, Yang Zhou, Weixue Huang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Science China. Life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ke DingState Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, 200032, China. dingk@sioc.ac.cn.
Yupeng LiDepartment of Pharmaceutical Sciences, School of Pharmacy and Border Biomedical Research Center, The University of Texas at El Paso, El Paso, 79968, USA.
Yang ZhouState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education, Guangzhou City Key Laboratory of Precision Chemical Drug Development, College of Pharmacy, Jinan University, Guangzhou, 511400, China.
Weixue HuangState Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, 200032, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Structure-based drug design (SBDD) has profoundly advanced the rational development of small molecule therapeutics by enabling the systematic optimization of drug-target interactions. A variety of molecular recognition models provide conceptual frameworks for understanding these interactions, thereby facilitating improvements in binding affinity, target selectivity, and pharmacokinetic profiles-key determinants of clinical success. To better emphasize the chemical nature of these interactions and to enhance the accessibility of rational drug design concepts for the synthetic chemistry community, we introduce chemical adaptation as a complementary framework to SBDD, offering an alternative, chemistry-oriented perspective for interpreting ligand-target interactions. This concept highlights deliberate, chemically driven strategies for optimizing ligand binding and improving drug-like characteristics. We classify chemical adaptation into four principal categories: ligand template adaptation (aligning the ligand's core structure with the topology of the target binding pocket), scaffold steric adaptation (refining the spatial orientation and steric complementarity of the molecular scaffold), functional group adaptation (modulating non-covalent interactions and physicochemical properties), and proximity-induced reactivity adaptation (leveraging covalent reactivity to strengthen target engagement). Collectively, these strategies underscore the necessity of precisely tailoring ligand structures to achieve optimal drug-like properties and offer a versatile, chemistry-centered framework applicable to the design of small molecule drugs across a broad spectrum of biological targets and therapeutic modalities.

Indexed as

Drug DesignDrug DevelopmentBinding SitesHumansLigandsModels, MolecularLigandschemical adaptationligand templatemacrocyclizationproximity-induced reactivitysteric hindrancestructure-based drug design

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.